TIAA CREF Investment Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

TIAA CREF Investment Management’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$290K	Buy	16,783 +2,436	+17%	+$44.2K	﹤0.01%	2787
2018 Q4	$253K	Hold	14,347	–	–	﹤0.01%	2822
2018 Q3	$260K	Sell	14,347 -3,565	-20%	-$73.1K	﹤0.01%	2924
2018 Q2	$350K	Buy	+17,912	New	+$336K	﹤0.01%	2909
2017 Q2	–	Sell	-32,995	Closed	-$389K	–	3208
2017 Q1	$389K	Sell	32,995 -1,194	-3%	-$14.5K	﹤0.01%	2878
2016 Q4	$448K	Sell	34,189 -946	-3%	-$12.7K	﹤0.01%	2884
2016 Q3	$509	Hold	35,135	–	–	﹤0.01%	2839
2016 Q2	$421K	Buy	35,135 +2,922	+9%	+$46.9K	﹤0.01%	2937
2016 Q1	$601K	Hold	32,213	–	–	﹤0.01%	2730
2015 Q4	$692K	Buy	32,213 +1,721	+6%	+$36.4K	﹤0.01%	2779
2015 Q3	$516K	Buy	30,492 +11,455	+60%	+$285K	﹤0.01%	2877
2015 Q2	$714K	Buy	+19,037	New	+$614K	﹤0.01%	2852

Other funds holding CBMG

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TIAA CREF Investment Management's CBMG Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Cellular Biomedicine Group, Inc. (CBMG) stake by 17% in Q1 2019, buying an estimated $44.2K and bringing the position to 16,783 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #2787.

TIAA CREF Investment Management first reported a position in CBMG in Q2 2015 and has held it in 12 quarters since. The position peaked at $714K in Q2 2015. 40 funds tracked by Wall St. Rank hold CBMG as of Q1 2019.

TIAA CREF Investment Management held 16,783 shares of Cellular Biomedicine Group, Inc. worth $290K as of Q1 2019.
TIAA CREF Investment Management bought 2,436 Cellular Biomedicine Group, Inc. shares in Q1 2019, an estimated $44.2K.
Cellular Biomedicine Group, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2787 holding.
TIAA CREF Investment Management first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and has held it in 12 quarters since.
TIAA CREF Investment Management's Cellular Biomedicine Group, Inc. position peaked at $714K in Q2 2015.
40 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.